Fresenius SE & Co. KGaA

Earnings Release • Oct 2, 2013

A Leading Global Health Care Group

For detailed financial information please see our annual/quarterly reports and/or conference call materials on our website.

Frankfurt stock exchange (DAX30): FRE US ADR program (OTC): FSNUY

Fresenius At a Glance

A Global Leader in Health Care Products and Services

• Sales >€20 bn, net income >€1 bn in 2013e
• Strong and well-diversified portfolio
• Global presence in approx. 100 countries
• Long-term opportunities in growing markets

Attractive total shareholder return: 10-year annual average of 24%

Strong and Balanced Health Care Portfolio

Dialysis products and services

Ownership: 31% Ownership: 100% Ownership: 100% Ownership: 77%

Hospital supply Hospital operations Hospital projects and services

i b i 2 0 2 G C 1 N t I t t o p e n c o m e o n o n r u r u
2 9 %	% 4 7	2 2 %	3 %

Evolving Industry Dynamics

Aging population and higher incidence of chronic diseases

World population age 60+ will more than double by 2050 to >2 bn (OECD)

Increasing health care spending in emerging markets

Increasing health care coverage and per capita spending (e.g. India: US\$59, China: US\$278, vs. USA: US\$8,608; WHO)

Continuing growth of generics

Approx. US\$18 bn branded IV drug sales (base: 2011) go off-patent in the U.S. by 2022

Rise of private providers in health care services

Further privatization of German hospital market Global opportunity to provide dialysis services (e.g. China, India)

Well Positioned for Future Growth

Fresenius Medical Care: Global Market Leader in Dialysis

• • Provide highest standard of patient care
• -High quality dialysis products & services
• -Complete therapy offerings
• -Vertical integration
• Service portfolio expansion and global clinic acquisitions; expand into new geographies

Industry Dynamics

Expected global patient growth: ~6% p.a. 2020e: ~3.8 million patients

2012 Sales: US\$13,800 m; EBIT: US\$2,329 m

Fresenius Kabi: A Worldwide Leading Hospital Supplier

• • Comprehensive product portfolio for critically and chronically ill patients:
• -IV Drugs
• -Clinical Nutrition
• -Infusion Therapy
• -Medical Devices / Transfusion Technology
• -Leading market positions; global market: >€25 bn1
• • Focus on organic growth driven by geographic product rollout and robust product pipeline
• • Aim to expand the business through selective acquisitions

2012 Sales by Region

2012 Sales: €4,539 m; EBIT: €934 m

Fresenius Helios: Leading Private Hospital Operator in Germany

• Acute Care Hospital Beds by Operator Acute and post-acute care in 74 proprietary hospitals
• High-quality medical care (e.g., mortality rate for heart failure and pneumonia >30% below German average)
• Two-pronged growth strategy: 3 − 5% organic sales growth, privatization growth opportunity
• Strong track record in hospital operations and acquisitions: targeting 12 − 15% EBIT margin within 6 years per individual clinic location

2012 Sales: €3,200 m; EBIT: €322 m

Fresenius Vamed: A Leading Global Specialist in Hospital Projects and Services

• Specialized in project development building hospital infrastructure and providing hospital services (technical services and operational management)
• Track record:

• • 600 health care projects in 70 countries successfully completed

• • Services provided to 140 hospitals and 50,000 beds globally
• Continuous demand for hospital infrastructure and operating efficiency; key markets Europe, Asia-Pacific, Africa

2012 Sales: €846 m; EBIT: €51 m

Excellent Financial Performance Driven by Strong Organic Growth and Acquisitions

Consistent Cash Generation and Proven Track Record of Deleveraging

4

Attractive Long-term Shareholder Returns

20th Consecutive Dividend Increase

Dividend growth aligned with EPS growth (before one-time items)

0 4 8 12 16 20 24DAX30Freseniusshare24.02% p.a. 10.15% p.a. %

Source: Bloomberg; dividends reinvested

Compounded annual total return Dec 31, 2002 − Dec 31, 2012

Fresenius Outperforms Index

Successful First Half 2013 – Earnings Outlook Raised

	2 0 3 H 1 1	G h t o r w
l S a e s	€ 9 9 8 7 m ,	9 %
E B I T	€ 1 4 4 8 m ,	2 %
f ( b ) N i i i t t t e n c o m e e o e o n e m e e m s r -	€ 8 2 4 m	2 % 1

OUTLOOK 2013

l h S t a e s g o r w t c ta t c a on s n ur re nc y	7 % 1 0 % ‒
h ( b f ) N i i i t t t t e n c o m e g r o w e o r e o n e m e e m s - t c ta t c a on s n re nc ur y	% % 1 1 1 4 ‒

Investment Highlights

• Diversified revenue and earnings base with four strong business segments
• Leading positions in non-cyclical markets with predictable growth
• Industry-leading organic growth in all business segments
• Strong earnings performance and cash flow generation
• Attractive shareholder returns
• Prudent financial management

Fresenius: 100 Years of Forward Looking Healthcare

Share Information

Share key facts

Number of shares¹ 178,763,259 WKN / ISIN 578560 / DE0005785604 Ticker symbol FRE Bloomberg symbol (XETRA) FRE GY Reuters symbol (XETRA) FREG.DE

ADR key facts

Ticker symbol FSNUY Exchange OTC-market Depositary bank Deutsche Bank

Ratio 8 ADRs = 1 ordinary share ADR CUSIP / ISIN 35804M105 / US35804M1053 Structure Sponsored Level I ADR

Safe Harbor Statement

This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements contained in this presentation.